UNASSIGNED: e21174 Background: Personalized medicine has become increasingly important in the management of oncology @entity1 . Traditional approaches require a large numbers of unselected @entity1 to enroll on clinical studies with empirically derived therapies. Newer approaches include analysis of @entity5 specimens to determine potential predictive and prognostic clinical biomarkers. Recently, a study by Von Hoff and colleagues utilized a molecular analysis of freshly biopsied @entity5 to determine gene array profile along with immunohistochemical staining in effort to generate potential targets for therapeutic intervention. This approach led to 28% of the study @entity1 achieving a 33% increase in progression free survival. @entity1636 ( @entity1636 ) occur in only one out of one million @entity1 and many @entity1 have @entity3 at the time of diagnosis (1). The rarity of this disease makes it difficult to study and with few treatment options the prognosis is poor (5). The standard management of this disease is largely surgical, with a role for adjuvant mitotane post-operatively, and palliative chemotherapy in the case of @entity3 (9). METHODS: Six consecutive unselected @entity1 at UCLA Medical Center were chosen for this study. The @entity1 had surgery at UCLA and had a portion of their @entity5 fresh frozen and sent CARIS MPI where molecular analysis was performed. A gene microarray profile that focused on 81 genes, potentially important in oncogenesis and oncomaintenance, was run as well as immunohistochemistry staining of 50 proteins important in cell growth and division. Genetic data were categorized, qualitatively reviewed, and attempts at correlations were made. RESULTS: The microarray data provided some consistencies across the @entity1 . All the @entity1 were found to overexpress DNA associated molecules such as; @entity14583 , @entity16071 , @entity19216 , and @entity16981 also found to be underexpressed were molecules involved in signaling pathways such as; @entity675 and @entity1015 . CONCLUSIONS: While many @entity5 have known @entity74 contributing to their molecular phenotype @entity1636 has yet to have any clearly defined molecular defect. This brief molecular study and clinical description of six @entity1636 @entity1 illustrates the heterogeneity of this disease.

Molecular analysis of @entity1636 ( @entity1636 ) XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'people'] @entity675 :: ('5156', 'Gene') :: ['PDGFRA'] @entity16071 :: ('6241', 'Gene') :: ['RRM2'] @entity19216 :: ('7083', 'Gene') :: ['TK1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'tumors'] @entity16981 :: ('7298', 'Gene') :: ['TYMS'] @entity1015 :: ('1890', 'Gene') :: ['ECGF1'] @entity1636 :: ('MESH:D018268', 'Disease') :: ['ACC', 'Adrenocortical carcinomas'] @entity74 :: ('MESH:D030342', 'Disease') :: ['genetic defects'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastatic disease'] @entity14583 :: ('7153', 'Gene') :: ['TOP2A']
@entity5 :: (MESH:D009369,Disease) :: ['tumors']
